Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

54.60 -2.11 (-3.72%)

Streaming Delayed Price Updated: 10:08 AM EST, Dec 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

34 35 Next >

6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy ↗

December 21, 2023

Should you buy CRISPR's stock on the dip?

Via The Motley Fool

Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock ↗

December 21, 2023

These stocks are currently going in different directions, but both could go up in a new bull market.

Via The Motley Fool

Is Vertex Pharmaceuticals Sitting on a Gold Mine? ↗

December 21, 2023

Vertex shares have climbed about 40% this year.

Via The Motley Fool

CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief ↗

December 20, 2023

The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy.

Via InvestorPlace

3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow ↗

December 20, 2023

CRISPR Therapeutics stock has increased in the double digits this year.

Via The Motley Fool

3 Genomics Stocks to Unlock the Future of Medicine ↗

December 19, 2023

Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use.

Via InvestorPlace

Where Will CRISPR Therapeutics Be in 5 Years? ↗

December 15, 2023

Does the recent approval make the stock a no-brainer buy?

Via The Motley Fool

After This Landmark Win, Is CRISPR Therapeutics a Buy? ↗

December 15, 2023

CRISPR Therapeutics stock already has advanced in the double digits this year.

Via The Motley Fool

Better Growth Stock: Archer Aviation or Prime Medicine? ↗

December 19, 2023

Which of these innovation-themed growth stocks is the better buy?

Via The Motley Fool

3 Healthcare Stocks That Could Help Make You a Millionaire ↗

December 19, 2023

These stocks each have reached an important turning point that could signal growth ahead.

Via The Motley Fool

2 Stocks Profiting From Unstoppable Trends That Could Make You Rich ↗

December 18, 2023

It's important to choose companies involved in trends that have long-term potential.

Via The Motley Fool

2 Stocks That Could Turn $1,000 Into $3,500 in 10 Years ↗

December 17, 2023

These businesses are exciting and can also lead to outsized long-term returns.

Via The Motley Fool

CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall? ↗

December 16, 2023

The benefits from its first drug launch will trickle in slowly, at least at first.

Via The Motley Fool

3 Fantastic Stocks That Could Enjoy a Santa Claus Rally ↗

December 16, 2023

These stocks could bring investors more than just a lump of coal for Christmas.

Via The Motley Fool

Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip ↗

December 16, 2023

This biotech could have more winners on the way.

Via The Motley Fool

Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development ↗

December 15, 2023

These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.

Via InvestorPlace

3 Small-Cap Stocks That Could Skyrocket 1000% by 2030 ↗

December 14, 2023

With the iShares Russell 2000 ETF (NYSE:IWM) on the move, investors should consider these small-cap stocks to buy.

Via InvestorPlace

Topics ETFs

Cathie Wood Just Dumped $40 Million of Coinbase Global (COIN) Stock ↗

December 14, 2023

Wood is moving away from fintech and Internet names like COIN stock. She's now favoring genomics and artificial intelligence companies.

Via InvestorPlace

Topics Artificial Intelligence

1 Biotech Stock That Could Be the Next Amgen ↗

December 13, 2023

The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.

Via The Motley Fool

Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences? ↗

December 13, 2023

Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy right now.

Via The Motley Fool

3 Gene-Editing Stocks With the Potential to Mint Millionaires ↗

December 13, 2023

Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.

Via InvestorPlace

Cathie Wood's Ark Invest Sells Nearly $11.5M Worth Of Coinbase Shares As Bitcoin, Crypto Rally Loses Steam ↗

December 12, 2023

Via Benzinga

Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine ↗

December 12, 2023

Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology.

Via Investor's Business Daily

Could Intellia Therapeutics Become the Next CRISPR Therapeutics? ↗

December 12, 2023

Intellia is approaching the finish line.

Via The Motley Fool

Cathie Wood's Ark Dumps $12.8M Worth Of Grayscale Bitcoin Trust Amid Crypto Rally Losing Wind In Sails ↗

December 11, 2023

On Monday, Cathie Wood-led Ark Invest made a significant move by selling over $12.8 million worth of Grayscale Bitcoin Trust (OTC:GBTC) shares, amidst fluctuating cryptocurrency prices.

Via Benzinga

Why CRISPR Stock Keeps Falling ↗

December 11, 2023

CRISPR just scored its first FDA victory -- but profits remain years away.

Via The Motley Fool

3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023 ↗

December 11, 2023

Some of the most explosive opportunities can be found in biotech stocks. In fact, as we head into New Year 2024, here are three to consider.

Via InvestorPlace

HP To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Monday ↗

December 11, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Bull Of The Day: Crispr Therapeutics ↗

December 11, 2023

CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old...

Via Talk Markets

Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug? ↗

December 11, 2023

A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider.

Via The Motley Fool

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.